The liver is a key organ for glucose and lipid metabolism. During feeding, hepatocytes increase glucose uptake in response to elevated glucose levels in the portal vein and increase glycogen and triacylglyceride synthesis. AKT is a key molecule for insulin signaling and glucose metabolism. On AKT activation, glucose influx is stimulated by activation of glycogen synthesis through glycogen synthase kinase (GSK)-3β. The facilitative glucose transporter (GLUT) 2 is predominantly expressed in the liver ([@B1]). Hepatic GLUT2 is located at the plasma membrane even in the absence of insulin stimulation; glucose uptake by GLUT2 is therefore not directly affected by insulin. Glucose increases GLUT2 mRNA levels in hepatocytes ([@B2]), resulting in increased glucose influx. Constitutive activity of AMP-activated protein kinase (AMPK) decreases glycogen synthesis accompanied by down-regulation of GLUT2 expression ([@B3]). Therefore, both AKT and AMPK are involved in glucose metabolism.

Acid sphingomyelinase (ASM) deficiency leads to Niemann-Pick disease. ASM has been reported to be involved in various cellular functions ([@B4]), including glucose and lipid metabolism. ASM activity is increased in the serum of type 2 diabetic patients ([@B5]). Sphingomyelinase induces GLUT4 translocation to the plasma membrane ([@B6], [@B7]) and increases glucose uptake by adipocytes ([@B7], [@B8]). A high-fat, high-cholesterol diet does not induce hepatic triacylglyceride accumulation in ASM-deficient mice (ASM^−/−^) under an LDL receptor-deficient condition ([@B9]). ASM hydrolyzes sphingomyelin to ceramide and phosphorylcholine. Ceramide has been identified as a bioactive mediator in various cellular functions, including apoptosis and the cell cycle ([@B10], [@B11]). Ceramide accumulation contributes to the development of type 2 diabetes ([@B12]). Indeed, inhibition of ceramide synthesis by myriocin, serine palmitoyltransferase inhibitor, or dihydroceramide desaturase improves insulin resistance induced by glucocorticoid or saturated fat ([@B13]). Ceramide induces insulin resistance by inactivation of AKT through protein phosphatase-2A and PKC-ζ ([@B14], [@B15]) or by inhibition of AKT translocation to the plasma membrane ([@B16]). In addition, ceramide inhibits AMPK activation in hepatoma cells ([@B17]).

Not only ceramide but also its metabolite sphingosine-1-phosphate (S1P) is involved in glucose metabolism. Ceramide is hydrolyzed by ceramidase to sphingosine, which is further phosphorylated to S1P by sphingosine kinase (SphK; ref. [@B18]). S1P stimulates AKT activation in human ([@B19]) and rodent hepatocytes ([@B20]) through the S1P receptor (S1PR). S1P signaling also increases glucose uptake *via* the insulin receptor and production of reactive oxygen species in C2C12 mouse myoblast cells ([@B21]). Because sphingolipids are important in glucose and lipid metabolism, we investigated the role of ASM in glucose and lipid metabolism in hepatocytes. In this study, we determined that ASM stimulates glucose uptake, glycogen deposition, and lipid accumulation *via* S1P formation and subsequent AKT activation. As a result, ASM deficiency causes glucose intolerance.

MATERIALS AND METHODS
=====================

Animals
-------

The experiments were conducted in accordance with the institutional guidelines of Gifu University and Columbia University. Sprague-Dawley male rats and male wild-type (C57BL/6J), ASM^−/−^, SphK1-deficient (SphK1^−/−^; refs. [@B20], [@B22]), and obese and diabetic *db/db* mice (C57BL/6 background) were used for this study.

Mice
----

ASM^−/−^ mice (C57BL/6 background) and SphK1^−/−^ mice (C57BL/6 background) ([@B23]), which lack the putative lipid kinase catalytic domain, were bred for studies. Obese and diabetic *db/db* mice (C57BL/6 background) were obtained from the Institute for Animal Reproduction (Ibaragi, Japan), and wild-type C57BL/6J mice were from Japan SLC (Shizuoka, Japan). Eight- to 10-wk-old male mice were used for in vivo studies.

Intraperitoneal glucose tolerance test (IPGTT)
----------------------------------------------

The 8- to 10-wk-old male mice (wild-type, *db/db*, or ASM^−/−^ mice) were deprived of food for 18 h. [d]{.smallcaps}-Glucose (2 mg/g body weight) was injected intraperitoneally, and blood glucose levels were monitored at 0, 30, 60, and 120 min after the injection using G checker (Sanko Junyaku, Tokyo, Japan). Values for area under the blood glucose curve after glucose loading were calculated. Serum insulin content was measured with a mouse insulin ELISA kit (Shibayagi, Gunma, Japan).

Primary hepatocyte cultures
---------------------------

Sprague-Dawley male rats (200--250 g) or mice (4 wk old) were anesthetized with ketamine and xylazine administered by intraperitoneal injection. Hepatocytes were then isolated by a nonrecirculating in situ collagenase perfusion of livers cannulating through the portal vein of rats or inferior vena cava of mice. Livers were first perfused in situ with 0.5 mM EGTA containing calcium-free salt solution, followed by perfusion with solution containing 0.02% collagenase D (Roche Diagnostics, Indianapolis, IN, USA). The liver was then gently minced on a Petri dish and filtered with polyamide mesh (3-60/42; Sefar America Inc., New York, NY, USA). Hepatocytes were washed 3 times and centrifuged at 50 *g* for 1 min. Cell viability was consistently \>90%, as determined by trypan blue exclusion. Cells were plated on dishes coated with rat collagen type I in Waymouth medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum with antibiotics (plating medium).

Cell treatment
--------------

After isolation from rat or mouse livers, hepatocytes were cultured in 10% FBS-containing medium for 4 h. Cells were then washed twice with PBS and changed to serum-free RPMI 1640 (Invitrogen) containing glucose (200 mg/dl) and antibiotics in the presence or absence of recombinant adenoviruses \[10 plaque forming units (PFU)/cell\]. After a 2-h incubation, the culture medium was changed to serum-free RPMI 1640 containing antibiotics, and the cells were incubated for an additional 16 h. Before stimulation with ASM (1 IU/ml; Sigma-Aldrich, St. Louis, MO, USA), SIP (1 μM; Sigma-Aldrich), or high-dose glucose (600 mg/dl), the cells were washed twice with PBS. The cells were pretreated with imipramine (50 μM; Sigma-Aldrich) for 1 h or with pertussis toxin (PTX) (Sigma-Aldrich) for 16 h in some experiments. The hepatocytes were then treated with or without ASM, SIP, or high-dose glucose, and incubated 8 h for glycogen, RNA, and protein extraction or 24 h for Oil Red O staining and triglyceride measurement. The experimental design is shown in Supplemental Fig. S1*A*.

Recombinant adenoviruses
------------------------

The adenovirus 5 (Ad5) variants Ad5GFP, Ad5CA-AKT, Ad5DN-AKT, Ad5CA-AMPK, and Ad5DN-AMPK express green fluorescent protein (GFP), constitutively active (CA)-AKT encoding an amino-terminal myristylation signal, dominant-negative (DN)-AKT, c-*myc*-CA-AMPK, and c-*myc*-DN-AMPK, respectively ([@B20], [@B24]). The recombinant replication deficient adenovirus Ad5ASM expressing ASM was constructed by an AdEasy Adenoviral Vector System (Stratagene, La Jolla, CA, USA). In brief, the full length of human ASM DNA was subcloned into pTrack adenoviral vector. The plasmid DNA was prepared by the alkaline lysis method and transfected into BJ5183-AD-1 electroporation-competent cells. The virus was grown in HEK293 cells and purified by banding twice on CsCl gradients, then dialyzed and stored at −20°C. The pTrack plasmid contains a GFP sequence driven under a CMV promoter, and the Ad5ASM expresses both ASM and GFP. Mice were infected with the adenoviruses (5×10^8^ PFU/mouse) by intravenous injection. IPGTT was performed on 3 d after the infection. The animals were humanely killed at 3 d for glycogen and protein extraction and at 7 d for Oil Red O staining and triglyceride measurement.

Glucose uptake
--------------

Primary cultured hepatocytes were treated with or without ASM for 2 h or infected with Ad5ASM or Ad5GFP, and then 2-deoxy-[d]{.smallcaps}-\[1-^3^H\]glucose (2 μCi/ml; Amersham Biosciences, Piscataway, NJ, USA) was added to the culture medium. After a further 1-h incubation, cells were washed 3 times with ice-cold PBS and lysed in 1% SDS and 200 mM NaOH. The amount of labeled glucose taken up was determined by scintillation counting.

Measurement of glycogen content
-------------------------------

After the treatment of hepatocytes for the indicated periods, the dish was placed on ice, washed with ice-cold PBS twice, and then incubated with 30% KOH for 30 min at room temperature. For the measurement of glycogen content in liver tissue, frozen liver tissues were homogenized in 30% KOH. Then, ethanol was added to the lysate, and glycogen was precipitated by centrifugation. The pellet was dissolved with H~2~O, and glycogen content was determined by anthrone reagent (2 mg anthrone/ml sulfuric acid). Glucose solution was used as a standard.

Oil Red O staining
------------------

For lipid droplet staining, the cells were fixed with 10% formalin and stained with Oil Red O working solution. Hematoxylin was used for counterstaining. For liver tissue, the frozen liver sections were cut at a thickness of 5 μm on a cryostat and stained with Oil Red O.

Measurement of triglyceride
---------------------------

After the treatment, the primary cultured hepatocytes were washed with PBS and scraped with methanol. For the measurement of triglyceride in liver tissue, frozen liver tissues were homogenized in PBS, and methanol was added to the lysate. The lipids were extracted by the method of Bligh and Dyer ([@B25]), and triglyceride content was measured using a triglyceride kit (L-type TG M with lipid calibrator; Wako, Osaka, Japan).

Western blot
------------

For the preparation of total cell proteins, cells or frozen liver tissues were homogenized in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 8.8; 150 mM NaCl; 10 mM EGTA; 1% Triton-X; 0.1% SDS; 1% deoxycholic acid; 0.3 mM PMSF; 1 mM sodium orthovanadate; 10 mM sodium fluoride; 0.1 mM sodium molybdate; and 0.5 mM 4-deoxypyridoxine). The proteins were separated by SDS-PAGE and were electrophoretically transferred onto nitrocellulose membrane. The membranes were first incubated with the primary antibodies, anti-phosphorylated-AKT (Ser-473; 9271; Cell Signaling Technology, Danvers. MA, USA), AKT (9272; Cell Signaling), phosphorylated-GSK3β (Ser-9, 9336; Cell Signaling), GSK3β (610201; BD Biosciences, San Jose, CA, USA), phosphorylated-AMPKα (Thr-172, 2531; Cell Signaling), AMPKα (2603; Cell Signaling), GLUT2 (sc-9116; Santa Cruz Biotechnology, Santa Cruz, CA, USA), ASM (sc-11352; Santa Cruz Biotechnology), and β-actin (Sigma-Aldrich) antibodies. Then, the membrane was incubated with the horseradish peroxidase-coupled secondary antibodies (Santa Cruz Biotechnology). Detection was performed with an ECL system (Amersham Biosciences), and the protein bands were quantified by densitometry using the ImageJ program (U.S. National Institutes of Health; <http://rsb.info.nih.gov/ij/>).

Quantitative real-time RT-PCR
-----------------------------

Extracted RNA from the cells was reverse-transcribed, and quantitative real-time PCR with probe-primer sets of GLUT2 and 18S ribosomal RNA (Applied Biosystems, Foster City, CA, USA) was performed using TaqMan analysis (ABI Prism 7000; Applied Biosystems). The changes were normalized based on 18S.

Mass spectrometric analysis of sphingolipids
--------------------------------------------

Electrospray ionization tandem mass spectrometry analysis was performed on a Thermo Finnegan TSQ 7000 triple quadruple mass spectrometer (Thermo Finnegan, San Jose, CA, USA), operating in multiple reaction monitoring positive ionization mode, as reported previously ([@B26]).

S1P formation
-------------

Primary rat hepatocytes were incubated with \[^3^H\]serine (2 μCi/ml)-containing medium for 12 h. Then, the medium was changed to serum-free RPMI 1640 medium containing \[^3^H\]serine with subsequent incubation with adenoviruses for an additional 18 h. The cellular lipids were extracted by the method of Bligh and Dyer ([@B25]) and separated on TLC plates in the solvent system of 1-butanol/acetic acid/water (60:20:20, v/v). The radiolabeled S1P spot was scraped off from the plates, and the radioactivity was measured in a liquid scintillation counter.

Statistical analysis
--------------------

The results shown are representative of ≥3 independent experiments. Data are expressed as means ± [sd]{.smallcaps} from ≥4 independent experiments. Data between groups were analyzed by Student\'s *t* test. Values of *P* \< 0.05 were considered statistically significant.

RESULTS
=======

Exogenous ASM improves glucose metabolism in mice
-------------------------------------------------

To explore the role of hepatic ASM on glucose and lipid metabolism, an adenovirus vector expressing human ASM, Ad5ASM, was used in this study. On administration of Ad5ASM into mice, ASM was preferentially expressed in the liver but not in muscle and adipose tissue (Supplemental Fig. S1*B, C*). As a result, ASM activity in the liver was increased (Supplemental Fig. S1*D*). Sufficient expression and activity of ASM in Ad5ASM-infected primary cultured hepatocytes were confirmed. This activity efficiently suppressed the level of sphingomyelins in hepatocytes (Supplemental Fig. S1*E* and **[Table 1](#T1){ref-type="table"}**). Initially, we investigated the effect of ASM in a glucose tolerance test and demonstrated that blood glucose levels were decreased in both wild-type (**[Fig. 1](#F1){ref-type="fig"}*A***) and diabetic *db/db* mice ([Fig. 1](#F1){ref-type="fig"}*B*) in which ASM was overexpressed by Ad5ASM, indicating that ASM improves glucose tolerance. Then, we used primary cultured hepatocytes to investigate the effect of ASM on glucose uptake. Exogenous administration or adenoviral introduction of ASM increased glucose uptake in hepatocytes ([Fig. 1](#F1){ref-type="fig"}*C*), suggesting that ASM improves glucose tolerance by increased hepatic glucose uptake. Next, we examined the role of ASM in glycogen synthesis. Exogenous ASM expression increased hepatic glycogen content in vivo ([Fig. 1](#F1){ref-type="fig"}*D*) and in vitro ([Fig. 1](#F1){ref-type="fig"}*E*) using primary cultured hepatocytes. We further examined the role of ASM in lipid metabolism. Exogenous ASM introduction increased hepatic lipid content and serum triglycerides (**[Fig. 2](#F2){ref-type="fig"}*A*,** ***B***) in vivo. We verified that ASM induces accumulation of lipid droplets and triglyceride in primary cultured hepatocytes ([Fig. 2](#F2){ref-type="fig"}*C*). These results indicate that ASM contributes not only to glucose uptake but also to the synthesis of glycogen and triglyceride in the liver.

###### 

Changes in the sphingolipid profile in Ad5ASM-infected hepatocytes

  Species      Ad5GFP             Ad5ASM
  ------------ ------------------ ----------------------------------------------------
  C14-SphM     31.5 ± 0.1         22.2 ± 1.8[\*](#TF1-1){ref-type="table-fn"}
  C16-SphM     6626.5 ± 261.3     4376.0 ± 210.8[\*](#TF1-1){ref-type="table-fn"}
  C18-SphM     2053.2 ± 65.0      1108.7 ± 53.4[\*](#TF1-1){ref-type="table-fn"}
  C18:1-SphM   260.9 ± 5.8        168.7 ± 5.1[\*](#TF1-1){ref-type="table-fn"}
  C20-SphM     1062.2 ± 20.0      564.4 ± 84.2[\*](#TF1-1){ref-type="table-fn"}
  C20:1-SphM   130.0 ± 2.6        79.3 ± 5.5[\*](#TF1-1){ref-type="table-fn"}
  C22-SphM     8397.5 ± 538.7     5223.5 ± 688.8[\*](#TF1-1){ref-type="table-fn"}
  C22:1-SphM   1221.8 ± 60.2      696.0 ± 109.1[\*](#TF1-1){ref-type="table-fn"}
  C24-SphM     24,630.7 ± 115.6   16,310.1 ± 2479.5[\*](#TF1-1){ref-type="table-fn"}
  C24:1-SphM   17,194.4 ± 630.6   10,981.6 ± 1385.0[\*](#TF1-1){ref-type="table-fn"}
  C14-Cer      5.8 ± 0.6          7.1 ± 1.5
  C16-Cer      181.5 ± 7.5        185.3 ± 4.3
  C18-Cer      39.3 ± 5.5         50.4 ± 1.3[\*](#TF1-1){ref-type="table-fn"}
  C-18:1-Cer   8.4 ± 0.9          10.1 ± 0.1[\*](#TF1-1){ref-type="table-fn"}
  C20-Cer      33.0 ± 5.1         42.8 ± 1.5
  C24-Cer      919.8 ± 70.5       1140.7 ± 82.5[\*](#TF1-1){ref-type="table-fn"}
  C24:1-Cer    547.0 ± 70.3       598.4 ± 3.8
  Sph          140.3 ± 19.0       248.6 ± 14.5[\*](#TF1-1){ref-type="table-fn"}

Primary cultured rat hepatocytes were infected with Ad5GFP or Ad5ASM. Sphingomyelin and the different ceramide species were examined by mass spectrometric analysis. Results are expressed as picomoles lipid per milligram protein; they represent means ± [sd]{.smallcaps} from 3 independent experiments. SphM, sphingomyelin; Cer, ceramide; Sph, sphingosine.

*P* \< 0.05.

![Ad5ASM improves glucose tolerance in mice. *A*, *B*) Wild-type (*A*) or diabetic *db/db* mice (*B*) were infected with Ad5GFP or Ad5ASM (5×10^8^ PFU/mouse), then deprived of food for 18 h, and IPGTT was performed by administering a glucose load of 2 mg/g body weight 3 d after the infection. Values of area under the blood glucose curve were calculated (right panels). *C*) Primary cultured rat hepatocytes were treated with ASM (1 U/ml) for 2 h (left panel) or infected with Ad5GFP or Ad5ASM (10 PFU/cell; right panel), followed by measurement of 2-deoxy-[d]{.smallcaps}-\[1-^3^H\]glucose uptake after a 1-h incubation period. *D*) Hepatic glycogen content in wild-type mice was determined under food-deprivation conditions at 3 d after the adenoviral infection. *E*) Glycogen content was determined in rat hepatocytes at 8 h after ASM treatment (left panel) or normal (200 mg/dl) and high-dose glucose (600 mg/dl) (right panel) treatment with Ad5GFP or Ad5ASM infection. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960001){#F1}

![ASM stimulates lipid accumulation. *A*) Wild-type mice were infected with Ad5GFP or Ad5ASM (5×10^8^ PFU/mouse). Hepatic lipid content was assessed by Oil Red O staining (left panel; original view ×200) and triglyceride measurement (right panel) in food-deprived wild-type mice at 7 d after the adenovirus infection. *B*) Serum triglycerides were determined in food-deprived wild-type mice at 7 d after the infection. *C*) Primary cultured rat hepatocytes were infected with Ad5GFP or Ad5ASM (10 PFU/cell). Lipid droplets were assessed by Oil Red O staining (original view ×800). Triglyceride level in hepatocytes was determined (right panel). Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960002){#F2}

ASM induces AKT activation
--------------------------

AKT is a key molecule in insulin signaling and glucose metabolism. We hypothesized that AKT is involved in ASM-mediated glucose, glycogen, and lipid metabolism. To prove this, we initially investigated whether AKT affects glucose and lipid metabolism in hepatocytes using adenoviral overexpression of DN- or CA-AKT (Ad5DN-AKT and Ad5CA-AKT, respectively). DN-AKT inhibited insulin-induced phosphorylation of AKT, thereby inhibiting glycogen deposition and lipid accumulation by insulin or high-dose glucose in primary cultured hepatocytes (data not shown). In contrast, a constitutively active form of AKT strongly phosphorylated GSK3β (Supplemental Fig. S2*A*), resulting in increased glycogen deposition and lipid accumulation (Supplemental Fig. S2*B* and data not shown). AKT is therefore crucial for glucose and lipid metabolism in hepatocytes. On the basis of the fundamental roles of AKT in glucose and lipid metabolism, we investigated the role of AKT in ASM-mediated glucose, glycogen, and lipid metabolism. First, we examined whether ASM alters AKT signaling. Food intake stimulates AKT and GSK3β phosphorylation in mouse liver (**[Fig. 3](#F3){ref-type="fig"}*A***). Introduction of exogenous ASM increased AKT activation under food-deprivation conditions and further increased under feeding conditions ([Fig. 3](#F3){ref-type="fig"}*A*) without increasing serum insulin levels (data not shown) in comparison with control virus-infected animals. We further tested the requirement for insulin in ASM-induced AKT activation. In insulin-free conditions, introduction of ASM still increased AKT and GSK3β phosphorylation in primary cultured rat hepatocytes ([Fig. 3](#F3){ref-type="fig"}*B*, left panel). High-dose glucose did not affect AKT and GSK3β phosphorylation in primary hepatocytes ([Fig. 3](#F3){ref-type="fig"}*B*, left panel). These results suggest that ASM-induced AKT activation is not mediated by insulin or a response to increased intracellular glucose. In contrast, overexpression of DN-AKT abolished ASM-mediated AKT and GSK3β activity ([Fig. 3](#F3){ref-type="fig"}*B*, right panel). DN-AKT overexpression also abolished ASM-induced glycogen deposition and lipid accumulation ([Fig. 3](#F3){ref-type="fig"}*C*, *D*). These results suggest that ASM regulates glucose, glycogen, and lipid metabolism *via* activation of AKT.

![DN-AKT eliminates the effect of ASM introduction. *A*) Wild-type mice were infected with Ad5GFP or Ad5ASM (5×10^8^ PFU/mouse), and the animals were killed in both nonfeeding (fasting; 18 h food deprivation) and feeding conditions at 3 d after the adenoviral infection. Protein extracts from liver tissue were subjected to immunoblot for phosphorylated (p)-AKT, AKT, p-GSK3β, and GSK3β. Relative densitometric intensity of p-AKT and p-GSK3β was determined for each protein band and normalized to AKT and GSK3β, respectively (bottom panels). *B*) Primary cultured rat hepatocytes infected with Ad5GFP or Ad5ASM (10 PFU/cell) were further infected with Ad5GFP or Ad5DN-AKT or treated with or without high-dose glucose (600 mg/dl; normal glucose, 200 mg/dl) for 8 h. Protein extracts from hepatocytes were subjected to immunoblot for p-AKT, AKT, p-GSK3β, and GSK3β. *C*) Primary cultured rat hepatocytes infected with Ad5GFP or Ad5ASM plus Ad5GFP or Ad5DN-AKT were treated with or without high-dose glucose. Glycogen content was determined in hepatocytes at 8 h after the high-dose glucose treatment. *D*) Primary cultured rat hepatocytes were infected with Ad5GFP or Ad5ASM plus Ad5GFP or Ad5DN-AKT. Lipid droplets were assessed by Oil Red O staining in hepatocytes (original view ×800). Results shown are representative of ≥3 independent experiments. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960003){#F3}

ASM decreases AMPK phosphorylation and increases GLUT2 expression in hepatocytes
--------------------------------------------------------------------------------

Because AMPK is an important component in glucose metabolism, the effects of ASM on AMPK signaling were examined. Glycogen deposition induced by high-dose glucose was increased by DN-AMPK and reduced by CA-AMPK (Supplemental Fig. S2*C*, *D*) with no observed effects on AKT and GSK3β phosphorylation (data not shown), indicating that AMPK activation reduced glycogen synthesis; this result is consistent with previous studies ([@B3]). Then, we assessed the role of AMPK in ASM-mediated effects. In the control virus-infected livers, food intake did not affect AMPK phosphorylation (**[Fig. 4](#F4){ref-type="fig"}*A***), consistent with a previous report ([@B27]). In contrast, introduction of ASM reduced AMPK phosphorylation in response to food intake ([Fig. 4](#F4){ref-type="fig"}*A*). ASM also increased food intake-related GLUT2 protein expression in the liver ([Fig. 4](#F4){ref-type="fig"}*A*). A previous study gave indirect evidence that high glycogen content represses AMPK activation in skeletal muscle ([@B28]). However, our data demonstrated that AMPK phosphorylation was reduced by ASM in primary cultured hepatocytes under normal glucose conditions ([Fig. 4](#F4){ref-type="fig"}*B*), in which the glycogen content was lower than that in Ad5GFP-infected cells cultured in high-dose glucose medium ([Fig. 1](#F1){ref-type="fig"}*E*). These results suggest that the AMPK inactivation by ASM is not mediated by a response to increased intracellular glycogen. In primary cultured hepatocytes, high-dose glucose slightly reduced AMPK phosphorylation ([Fig. 4](#F4){ref-type="fig"}*B*), as shown in a previous report in HepG2 hepatoblastoma cells ([@B29]), suggesting that the refractoriness of AMPK by food intake was probably due to systemic mediators. In addition to AMPK, GLUT2 protein and mRNA levels were increased in ASM-expressing primary hepatocytes ([Fig. 4](#F4){ref-type="fig"}*B*, *C*). CA-AMPK partially inhibited glycogen deposition and lipid accumulation induced by ASM ([Fig. 4](#F4){ref-type="fig"}*D, E*). These results suggest that reduced AMPK activation is also crucial for ASM-mediated glucose metabolism.

![ASM decreases AMPK phosphorylation and increases GLUT2 expression. *A*, *B*) Wild-type mice were infected with Ad5GFP or Ad5ASM (5×10^8^ PFU/mouse), and the animals were killed in both nonfeeding (fasting; 18 h food deprivation) and feeding conditions at 3 d after the adenoviral infection. Primary cultured rat hepatocytes infected with Ad5GFP or Ad5ASM (10 PFU/cell) were cultured in normal (200 mg/dl) or high-dose glucose (600 mg/dl) conditions for 8 h. Left panels: protein extracts from the liver tissue (*A*) or the hepatocytes (*B*) were subjected to immunoblot for phosphorylated (p)-AMPK, AMPK, GLUT2, and β-actin. Right panels: relative densitometric intensity of p-AMPK and GLUT2 was determined for each protein band and normalized to AMPK and β-actin, respectively. *C*). mRNA levels of GLUT2 in hepatocytes were determined by quantitative real-time RT-PCR and normalized by 18S ribosomal RNA. *D*) Primary cultured rat hepatocytes infected with Ad5GFP or Ad5CA-AMPK were further infected with Ad5GFP or Ad5ASM. Cells were then incubated in normal or high-dose glucose conditions for 8 h. Glycogen content in hepatocytes was determined. *E*) Primary cultured rat hepatocytes were infected with Ad5GFP, Ad5CA-AMPK, and/or Ad5ASM. Lipid droplets in hepatocytes were assessed by Oil Red O staining (original view ×800). Results shown are representative of ≥3 independent experiments. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960004){#F4}

ASM activates AKT through the SphK/S1P pathway
----------------------------------------------

ASM hydrolyzes sphingomyelin into ceramide, which is further hydrolyzed and phosphorylated by ceramidase and SphK to form S1P. Because S1P activates AKT in hepatocytes ([@B20]), we investigated the contribution of S1P generation to ASM-mediated glucose and lipid metabolism. The ASM-induced phosphorylation of AKT and GSK3β was reduced in SphK1^−/−^ hepatocytes (**[Fig. 5](#F5){ref-type="fig"}*A***). Of note, S1P formation was inhibited in SphK1^−/−^ cells ([Fig. 5](#F5){ref-type="fig"}*B*, left panels). Overexpression of neutral ceramidase (NCD) or exogenous S1P activated AKT ([Fig. 5](#F5){ref-type="fig"}*B*, middle and right panels) in hepatocytes, as we reported previously ([@B20]). These results suggest that S1P generated by the breakdown of sphingomyelin contributes to ASM-induced AKT activation. We then examined the involvement of S1PR. Hepatocytes were treated with PTX because S1PRs coupled with G~i~ are sensitive to PTX. ASM-mediated AKT activation was reduced by PTX treatment ([Fig. 5](#F5){ref-type="fig"}*C*), indicating that ASM generates S1P, which further activates AKT, at least partially *via* S1PRs. ASM-induced glycogen deposition and lipid accumulation were also reduced in SphK1^−/−^ hepatocytes (**[Fig. 6](#F6){ref-type="fig"}*A*,** ***B***), whereas the sphingomyelin and ceramide levels were similar to those in wild-type hepatocytes (data not shown). Moreover, SphK1^−/−^ mice did not show hepatic steatosis by exogenous ASM introduction ([Fig. 6](#F6){ref-type="fig"}*C*). In contrast to AKT, AMPK was not affected by S1P administration or NCD overexpression ([Fig. 5](#F5){ref-type="fig"}*B*, middle panel). As in wild-type mice, SphK1^−/−^ mice expressing exogenous ASM showed decreased phosphorylation of AMPK ([Fig. 5](#F5){ref-type="fig"}*A*), indicating that the SphK/S1P pathway is not required for ASM-induced AMPK down-regulation.

![ASM-induced AKT phosphorylation is suppressed in SphK1^−/−^ hepatocytes. *A*) Primary cultured mouse hepatocytes isolated from SphK1^+/+^ or SphK1^−/−^ mice were infected with Ad5GFP or Ad5ASM (10 PFU/cell). Protein extracts from the hepatocytes were subjected to immunoblot for phosphorylated (p)-AKT, AKT, p-GSK3β, GSK3β, p-AMPK, AMPK, and β-actin. *B*) \[^3^H\]Serine-labeled hepatocytes from SphK1^+/+^ or SphK1^−/−^ mice were infected with Ad5GFP or Ad5ASM. Radiolabeled S1P was measured (left panels). Primary cultured rat hepatocytes were treated with or without S1P (1 μM) for 8 h (middle top panel). Primary cultured rat hepatocytes were infected with Ad5GFP or adenovirus expressing human neutral ceramidase (Ad5NCD) (middle bottom panel). Protein extracts from the hepatocytes were subjected to immunoblot for p-AKT, p-AMPK, and β-actin. *C*) Primary cultured rat hepatocytes were infected with Ad5GFP or Ad5ASM (10 PFU/cell), and incubated for 2 h. Then, cells were treated with or without the indicated concentration of PTX for 24 h. Top panel: protein extracts from hepatocytes were subjected to immunoblot for p-AKT and AKT. Relative densitometric intensity of p-AKT and p-AMPK was determined for each protein band of the sample and normalized to AKT and AMPK, respectively (*A*, *B*, right panels; *C*, bottom panel). Results shown are representative of ≥3 independent experiments. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960005){#F5}

![ASM-induced glycogen deposition and lipid accumulation are suppressed in SphK1^−/−^ hepatocytes. *A*) Primary cultured hepatocytes isolated from SphK1^+/+^ or SphK1^−/−^ mice were infected with Ad5GFP or Ad5ASM. Glycogen content in hepatocytes was determined. *B*) Lipid droplets in SphK1^+/+^or SphK1^−/−^ hepatocytes infected with Ad5GFP or Ad5ASM were assessed by Oil Red O staining (original view ×800). *C*) SphK1^+/+^ or SphK1^−/−^ mice were infected with Ad5GFP or Ad5ASM, followed by assessment for hepatic lipid content by Oil Red O staining (left panel; original view ×200) and triglyceride measurement (right panel) in food-deprivation conditions at 7 d after the infection (original view ×200). Results shown are representative of ≥3 independent experiments. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960006){#F6}

ASM deficiency inhibits glucose uptake, glycogen deposition, and lipid accumulation in hepatocytes
--------------------------------------------------------------------------------------------------

Finally, we tested whether ASM deficiency causes glucose intolerance. Sphingomyelin accumulation and ceramide reduction were observed in hepatocytes isolated from ASM^−/−^ mice (Supplemental Table S1). Blood glucose levels in ASM^−/−^ mice were higher than those in ASM^+/+^ mice throughout the IPGTT period without any changes in insulin levels (**[Fig. 7](#F7){ref-type="fig"}**). To further investigate the specific role of ASM in hepatocytes, primary hepatocytes were isolated and treated with high-dose glucose (600 mg/dl), which increased glycogen levels (**[Fig. 8](#F8){ref-type="fig"}*A***). Imipramine, a tricyclic antidepressant, causes proteolysis of the active 72-kDa ASM form, thus inhibiting ASM activity ([@B30]). Pretreatment with imipramine inhibited high-dose glucose-induced glycogen deposition ([Fig. 8](#F8){ref-type="fig"}*A*), as did the knockout of ASM in mouse hepatocytes ([Fig. 8](#F8){ref-type="fig"}*B*). Moreover, high-dose glucose increased lipid droplets in primary hepatocytes, and imipramine or ASM deficiency suppressed this effect ([Fig. 8](#F8){ref-type="fig"}*C*, *D*). These results suggest that high-dose glucose increases glucose uptake, resulting in glycogen deposition and lipid accumulation in hepatocytes. In contrast, ASM deficiency inhibits glucose uptake, glycogen deposition, and lipid accumulation, resulting in glucose intolerance. In ASM^−/−^ mice, similar levels of GSK3β phosphorylation were induced by food intake, whereas GLUT2 induction was reduced in comparison to the livers of ASM^+/+^ mice (**[Fig. 9](#F9){ref-type="fig"}*A***). Reduction of AMPK phosphorylation and induction of GLUT2 by high-dose glucose were inhibited in ASM^−/−^ hepatocytes ([Fig. 9](#F9){ref-type="fig"}*B*), whereas high-dose glucose did not affect AKT phosphorylation (data not shown). These results suggest that glucose intolerance in ASM^−/−^ mice was due, at least in part, to insufficient reduction of AMPK activity and induction of GLUT2.

![ASM^−/−^ mice were glucose intolerant. *A*) ASM^+/+^ and ASM^−/−^ mice were deprived of food for 18 h, and IPGTT was performed by administering a glucose load of 2 mg/g body weight. Serial glucose (left panel) and insulin (right panel) were measured at the indicated time points. Blood glucose values for area under the curve (AUC) were calculated (middle panel). Results shown are representative of ≥3 independent experiments. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960007){#F7}

![Inhibition of ASM impairs glucose uptake and glycogen deposition in primary cultured hepatocytes. *A*) Primary cultured rat hepatocytes were treated with normal (200 mg/dl) or high-dose glucose (600 mg/dl) with or without imipramine for the indicated periods of time. *B*) Primary cultured mouse hepatocytes from ASM^+/+^ and ASM^−/−^ mice were treated with normal or high-dose glucose for 8 h. Glycogen content in hepatocytes was measured. *C*) Primary cultured rat hepatocytes were treated with normal or high-dose glucose with or without imipramine for 24 h. *D*) Primary cultured hepatocytes from ASM^+/+^ or ASM^−/−^ mice were treated with normal or high-dose glucose for 24 h. Lipid droplets were assessed by Oil Red O staining in hepatocytes (original view ×800). Results shown are representative of ≥3 independent experiments. Data are means ± [sd]{.smallcaps} from ≥4 independent experiments. \**P* \< 0.05.](z380041181960008){#F8}

![Inhibition of ASM suppresses GLUT2 induction. *A*) ASM^+/+^ and ASM^−/−^ mice were killed in both nonfeeding (fasting; 18 h food deprivation) and feeding conditions. Protein extracts from liver tissue were subjected to immunoblot for phosphorylated (p)-GSK3β, GSK3β, GLUT2, and β-actin (left panel). Relative densitometric intensity of p-GSK3β (middle panel) and GLUT2 (right panel) was determined for each protein band of the liver tissue sample and normalized to GSK3β and β-actin, respectively. *B*) Primary cultured hepatocytes from ASM^+/+^ and ASM^−/−^ mice were treated with normal (200 mg/dl) or high-dose glucose (600 mg/dl) for 8 h. Protein extracts from hepatocytes were subjected to immunoblot for p-AMPK, AMPK, GLUT2, and β-actin. Results shown are representative of ≥3 independent experiments. \**P* \< 0.05.](z380041181960009){#F9}

DISCUSSION
==========

The present study addresses the contributions of ASM to glucose and lipid metabolism in the liver. The sphingomyelin/ceramide/S1P pathway is involved in glucose metabolism ([@B6]--[@B9], [@B12]--[@B14], [@B21]). Food intake reduced most sphingomyelin species in the mouse liver (Supplemental Table S2). Likewise, high-dose glucose reduced sphingomyelin species in primary cultured hepatocytes (Supplemental Table S2), suggesting that this pathway is related to glucose metabolism in hepatocytes. In our study using hepatocytes, ASM induced insulin-like effects such as glucose uptake, glycogen deposition, and lipid accumulation *via* S1P-mediated AKT activation. Ceramide attenuates insulin signaling, including AKT activation ([@B14]--[@B16]), thereby contributing to insulin resistance through multiple pathways ([@B13], [@B15]). In primary cultured hepatocytes, the effect of ASM introduction on ceramide level was smaller than that in sphingomyelin degradation, suggesting that the generated ceramide is further converted to S1P. Ceramide and S1P often exert opposing effects; thus, the balance between these two sphingolipids may be important for AKT activation. During ASM activation, the balance is inclined toward S1P, resulting in AKT activation. Indeed, ASM did not activate AKT in SphK1^−/−^ hepatocytes, suggesting that ASM mediates insulin-like effects *via* S1P formation. S1P acts as a ligand for the S1PRs and also as an intracellular second messenger ([@B31], [@B32]). Among S1PRs, G~i~-associated S1PR1 ([@B33]) is mainly expressed in the liver ([@B34]), and PTX pretreatment inhibited exogenous S1P-induced AKT phosphorylation in primary cultured hepatocytes (data not shown), suggesting that S1P may activate AKT through predominantly S1PR1. PTX treatment partially inhibits ASM-induced AKT activation, suggesting that the generated S1P activates AKT at least partially *via* S1PRs and may also activate AKT through receptor-independent mechanisms.

In addition to AKT, AMPK also contributes to glucose metabolism. AMPK is a serine/threonine protein kinase that senses the immediate availability of cellular energy. Activated AMPK switches on catabolic pathways and switches off protein, carbohydrate, and lipid biosynthesis (anabolic pathways; ref. [@B35]). Activation of AMPK in the liver reduces glycogen synthesis and lipogenesis as well as expression of GLUT2 ([@B3]). Activation of AMPK by 5-amino-4-imidazolecarboxamide riboside diminishes GLUT2 expression in primary cultured hepatocytes ([@B36]). Indeed, DN-AMPK increased glycogen deposition and lipid accumulation in primary hepatocytes and HepG2 cells (data not shown and ref. [@B37]). Thus, in addition to increased AKT activation, reduced AMPK activation may be associated with another anabolic effect of ASM. Ceramide decreases ([@B38]) but S1P increases ([@B39]) AMPK phosphorylation in endothelial cells. In our study, ASM-induced AMPK inhibition in hepatocytes was independent of S1P. Thus, the decrease in AMPK activity may be due to ceramide processed by ASM.

Ad5ASM-infected mice showed improved glucose tolerance. Because adenovirus preferentially infects hepatocytes, the decrease in blood glucose was due to a variation of hepatic glucose metabolism, although sphingolipids have roles in glucose metabolism in muscle ([@B40]) and adipocytes ([@B6]--[@B8]). The ASM-induced decrease in blood glucose may be attributed to increased uptake of hepatic glucose rather than decreased production, because introduction of ASM did not affect the activity of adenylate cyclase, the glucagon target enzyme, in primary cultured rat hepatocytes (data not shown). The effects of ASM on hepatocytes are comparable to those of insulin. However, the introduction of hepatic ASM improved hyperglycemia in *db/db* mice with type 2 diabetes without increasing insulin levels (data not shown), indicating that ASM may reduce blood glucose regardless of the presence of insulin resistance. Instead of decreasing blood glucose, ASM increased hepatic triglyceride content, suggesting that ASM stimulates lipogenesis, in which transported glucose is converted to triacylglycerol ([@B41]). The effects of exogenous ASM in the liver are similar to the effects of deletion of hepatic phosphatase and tension homolog on chromosome 10 (PTEN), which is a negative regulator of AKT. Deletion of PTEN in the liver results in hyperphosphorylation of hepatic AKT and improves glucose tolerance but induces fatty liver in mice ([@B42]).

ASM^−/−^ mice are glucose intolerant. The abnormality is not due to inactivation of the AKT/GSK3β pathway but is due, in part, to insufficient reduction of AMPK activity and induction of GLUT2. In addition, crosstalk may occur between ASM and various signaling pathways, including those of glucose and lipid metabolism, because ASM regulates sphingolipids in lipid raft microdomains that function as platforms for signal transduction and protein sorting ([@B18]). For example, disruption of lipid raft microdomains or chronic ethanol exposure inhibits localization of TC10 to lipid rafts, which induces GLUT4 translocation and glucose intake without affecting phosphatidylinositol-3 kinase/AKT signaling in adipocytes ([@B43], [@B44]). Pretreatment with imipramine inhibited high-dose glucose-induced lipid accumulation in rat hepatocytes, as did the knockout of ASM in mouse hepatocytes. As reported previously, the ASM inhibitor desipramine attenuates triglyceride increase by high-dose palmitic acid treatment in HepG2 cells ([@B9]). Moreover, a high-fat, high-cholesterol diet does not induce hepatic triacylglyceride accumulation in ASM^−/−^ mice under LDL receptor-deficient conditions ([@B9]). These observations further support the role of ASM as a regulator of triglyceride synthesis in addition to glucose uptake. Further studies will determine the precise mechanism underlying the anabolic effects of ASM and its activation and ceramide/S1P regulation ([@B45]). The hypothetical roles of ASM are schematically summarized in **[Fig. 10](#F10){ref-type="fig"}**.

![Hypothetical signals induced by ASM. Acid sphingomyelinase regulates glucose and lipid metabolism through AKT activation and AMPK suppression in hepatocytes. AKT activation is induced through S1P formation. AMPK suppression increases GLUT2 expression.](z380041181960010){#F10}

In conclusion, overexpression of ASM in the liver improves glucose tolerance in both wild-type and diabetic *db/db* mice. ASM stimulates glucose uptake, glycogen deposition, and lipid accumulation in hepatocytes *via* AKT and GSK3β phosphorylation, which requires S1P formation. In addition, ASM decreases AMPK phosphorylation through ceramides, leading to GLUT2 up-regulation. Indeed, inactivation of ASM produces glucose intolerance in hepatocytes. Targeting ASM may become a new therapeutic strategy in type 2 diabetes.
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